Cardiotoxicity related to treatment with anti-HER2 therapies is reassuringly low and resolution rates are high, allowing most patients to continue their breast cancer treatment, Australian research shows. A study of 287 patients with HER2 positive advanced breast cancer from the Australian TABITHA registry, found 6% of patients experienced mainly asymptomatic cardiotoxicity associated with anti-HER2 monotherapy ...
Low cardiotoxicity risk with anti-HER2 agents shows treatment can continue
By Mardi Chapman
19 Aug 2020